Industry News IQVIA Institute BioSpace
IQVIA: About 90% of 2016–2020 Drug Launches Won't Recoup Their Costs
- IQVIA analyzed 825 novel US launches and projects that about 90% of medicines launched in 2016–2020 will not earn enough lifetime revenue to cover costs.
- Positive-return launches fell from about half in the early 1990s to under one in ten.
- Capitalized R&D cost per medicine rose from about $366M for 1991 launches to over $3.2B for 2020, with shorter product life cycles and lower success rates blamed.
The headline is a projection against a capitalized-cost model, so the 90% moves with its assumptions on cost of capital and failure allocation. Still, the direction explains the 2026 pattern: buy late, buy de-risked, and lean on blockbusters. A sharper reading: average economics hide a fat tail, so portfolio concentration, not average R&D efficiency, is what deal-makers should read this for.
Source: BioSpace ↗ Rising costs leave 9 in 10 new medicines unprofitable, IQVIA finds